The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Robotic Process Automation in Finance – What’s the Buzz and Why Should You Care
Robotic Process Automation in Finance – Transforming the Industry How does Implementing RPA in Finance help Overcome these…
FasTest Appoints Boyle VP of Global Sales
FasTest Inc., announced the appointment of Brian Boyle as the company’s new vice president of Global Sales, effective…
Quality Deserves a Bigger Slice of the Pie
Quality might in theory be top priority, but most manufacturing operations run on ROI (return on investment). You…